Atara Biotherapeutics (ATRA) Price & Analysis

Compare

1,156 Followers

ATRA Stock Chart & Stats

Day’s Range― - ―

52-Week Range$5.01 - $18.71

Previous CloseN/A

Volume32.09K

Average Volume (3M)65.84K

Market Cap

$88.77M

Enterprise Value$131.17M

Total Cash (Recent Filing)$22.32M

Total Debt (Recent Filing)$15.43M

Price to Earnings (P/E)―

Beta0.95

Next Earnings

Nov 18, 2025

EPS Estimate

-0.67

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.19

Shares Outstanding7,023,032

10 Day Avg. Volume68,665

30 Day Avg. Volume65,840

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap1.48

Enterprise Value/Revenue0.70

Enterprise Value/Gross Profit0.86

Enterprise Value/Ebitda9.17

Forecast

1Y Price Target

$15.00

Price Target Upside21.46% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering4

Bulls Say, Bears Say

Bulls Say

Cost ManagementAtara is transferring all tab-cel development and manufacturing costs to Pierre Fabre - limiting cash burn.

Financial MilestonesIf the FDA approves tab-cel, it will trigger a $40 million milestone payment from Pierre Fabre to Atara, with additional commercial milestones and double-digit tiered royalties also possible.

Regulatory ApprovalFDA has accepted the tab-cel resubmission for priority review, a meaningful step toward first approved therapy in US for EBV+ PTLD.

Bears Say

Financial ConstraintsWe expect Atara to require additional funding even if EBVALLO is approved.

Operational ChallengesDue to current capital constraints, ATRA has paused the '3219/'3431 CAR-T programs and cut headcount.

Regulatory RisksRisks include the potential rejection of the tab-cel BLA resubmission by the FDA and setbacks with other pipeline candidates.

Atara Biotherapeutics News

Atara Biotherapeutics reports Q2 EPS 19c vs. ($3.10) last year

Cash, cash equivalents and short-term investments as of June 30, 2025, totaled $22.3 million, as compared to $13.8...

17d ago

ATRA

Atara Biotherapeutics: Hold Rating Amid Tab-cel Developments and Financial Uncertainty

H.C. Wainwright analyst Robert Burns has reiterated their neutral stance on ATRA stock, giving a Hold rating on...

10d ago

ATRA

ATRA Upcoming Earnings Report: What to Expect?

Atara Biotherapeutics Inc (ATRA) is scheduled to report 2nd quarter earnings on 08/11/2025. Regarding Q2 estimates, Wall Street...

20d ago

ATRA

Atara Biotherapeutics announces FDA acceptance of tabelecleucel BLA

Atara Biotherapeutics (ATRA) and Pierre Fabre Pharmaceuticals, or PFP, announced the acceptance by FDA of the Biologics License...

1M ago

ATRA

Atara Biotherapeutics announces FDA acceptance of BLA for tabelecleucel

Atara Biotherapeutics (ATRA) announced that the FDA has accepted the filing of its biologics license application for tabelecleucel...

1M ago

ATRA

Atara Biotherapeutics: Strategic Advancements and Financial Stability Support Buy Rating

John Newman, an analyst from Canaccord Genuity, maintained the Buy rating on Atara Biotherapeutics. The associated price target...

1M ago

ATRA

Atara Biotherapeutics Resubmits BLA for Tab-cel to FDA

Atara Biotherapeutics ( ($ATRA) ) has shared an update. On July 14, 2025, Atara Biotherapeutics announced the resubmission...

2M ago

ATRA

Atara Biotherapeutics Holds Annual Stockholders Meeting

Atara Biotherapeutics ( ($ATRA) ) has provided an update. On June 10, 2025, Atara Biotherapeutics held its annual...

3M ago

ATRA

Atara Biotherapeutics appoints Huang, Subramanian to board of directors

Atara Biotherapeutics (ATRA) announced the appointment of James Huang and Nachi Subramanian to its Board of Directors, effective...

3M ago

ATRA

Atara Biotherapeutics Reports Strong Q1 2025 Results

Atara Biotherapeutics Inc ( ($ATRA) ) has released its Q1 earnings. Here is a breakdown of the information...

3M ago

ATRA

Atara Biotherapeutics Announces $16M Stock Offering

Atara Biotherapeutics ( ($ATRA) ) has shared an announcement. On May 14, 2024, Atara Biotherapeutics entered into an...

3M ago

ATRA

Buy Rating for Atara Biotherapeutics: Strategic Focus and Financial Positioning Ahead of Key FDA Meeting

Analyst John Newman of Canaccord Genuity maintained a Buy rating on Atara Biotherapeutics (ATRA – Research Report), retaining...

3M ago

ATRA

Atara Biotherapeutics Appoints New Board Members Amid Restructuring

Atara Biotherapeutics ( ($ATRA) ) has shared an update. On May 14, 2025, Atara Biotherapeutics announced the appointment...

4M ago

ATRA

Atara Biotherapeutics Announces Major Workforce Reduction

Atara Biotherapeutics ( ($ATRA) ) has shared an announcement. On May 12, 2025, Atara Biotherapeutics, Inc. announced a...

4M ago

ATRA

ATRA FAQ

What was Atara Biotherapeutics’s price range in the past 12 months?

Atara Biotherapeutics lowest stock price was $5.00 and its highest was $18.70 in the past 12 months.

What is Atara Biotherapeutics’s market cap?

Atara Biotherapeutics’s market cap is $88.77M.

When is Atara Biotherapeutics’s upcoming earnings report date?

Atara Biotherapeutics’s upcoming earnings report date is Nov 18, 2025 which is in 81 days.

How were Atara Biotherapeutics’s earnings last quarter?

Atara Biotherapeutics released its earnings results on Aug 11, 2025. The company reported $0.19 earnings per share for the quarter, beating the consensus estimate of -$0.066 by $0.256.

Is Atara Biotherapeutics overvalued?

According to Wall Street analysts Atara Biotherapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Atara Biotherapeutics pay dividends?

Atara Biotherapeutics does not currently pay dividends.

What is Atara Biotherapeutics’s EPS estimate?

Atara Biotherapeutics’s EPS estimate is -0.67.

How many shares outstanding does Atara Biotherapeutics have?

Atara Biotherapeutics has 7,023,032 shares outstanding.

What happened to Atara Biotherapeutics’s price movement after its last earnings report?

Atara Biotherapeutics reported an EPS of $0.19 in its last earnings report, beating expectations of -$0.066. Following the earnings report the stock price went up 11.822%.

Which hedge fund is a major shareholder of Atara Biotherapeutics?

Among the largest hedge funds holding Atara Biotherapeutics’s share is Woodline Partners LP. It holds Atara Biotherapeutics’s shares valued at 0.

Atara Biotherapeutics Stock Smart Score

Outperform

Fundamentals

Return on Equity

1063.61%

Trailing 12-Months

Asset Growth

-68.54%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Atara Biotherapeutics

Atara Biotherapeutics (ATRA) is a clinical-stage biotechnology company focused on developing innovative T-cell immunotherapy treatments for patients with cancer and autoimmune diseases. The company specializes in allogeneic T-cell therapies, leveraging its proprietary technology to create off-the-shelf products that aim to harness the immune system to fight diseases. Atara's core products include ATA188, a T-cell therapy targeting Epstein-Barr virus-associated diseases, and ATA3219, which is aimed at treating various malignancies.

Atara Biotherapeutics (ATRA) Earnings & Revenues

Historic Earnings Reports

ATRA Stock 12 Month Forecast

Average Price Target

$15.00

▲(21.46% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"$5","20":"$20","8.75":"$8.75","12.5":"$12.5","16.25":"$16.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":17,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$17.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":15,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$15.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$12.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,8.75,12.5,16.25,20],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2024","6":"Dec<br/>2024","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.55,11.96923076923077,12.38846153846154,12.807692307692308,13.226923076923077,13.646153846153847,14.065384615384616,14.484615384615385,14.903846153846153,15.323076923076924,15.742307692307692,16.161538461538463,16.58076923076923,{"y":17,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.55,11.815384615384616,12.080769230769231,12.346153846153847,12.611538461538462,12.876923076923077,13.142307692307693,13.407692307692308,13.673076923076923,13.938461538461539,14.203846153846154,14.46923076923077,14.734615384615385,{"y":15,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.55,11.584615384615386,11.61923076923077,11.653846153846155,11.688461538461539,11.723076923076924,11.757692307692308,11.792307692307693,11.826923076923077,11.861538461538462,11.896153846153846,11.930769230769231,11.965384615384615,{"y":12,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":19.27,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.12,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.11,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.36,"date":1719792000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":10.4,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.71,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.14,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":13.31,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 9</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":6.91,"date":1740787200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":7.56,"date":1746057600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":8,"date":1748736000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":7.8,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.55,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >